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Abstract  29 
The molecular mechanisms leading to aryl hydrocarbon receptor interacting protein (AIP) mutation-30 
induced aggressive, young-onset growth hormone-secreting pituitary tumors are not fully understood. 31 
In this study, we have identified that AIP mutation positive tumors are infiltrated by a large number of 32 
macrophages compared to sporadic tumors. Likewise, tissue from pituitary-specific Aip-knockout 33 
(AipFlox/Flox;Hesx1Cre/+) mice recapitulated this phenotype. Our human pituitary tumor transcriptome 34 
data revealed the ‘epithelial-to-mesenchymal transition (EMT) pathway’ as one of the most 35 
significantly altered pathways in AIPpos tumors. Our in vitro data suggest that bone marrow-derived 36 
macrophage-conditioned media induces more prominent EMT-like phenotype and enhanced 37 
migratory and invasive properties in Aip-knockdown somatomammotroph cells compared to non-38 
targeting controls. We identified that tumor-derived cytokine CCL5 is up-regulated in AIP mutation 39 
positive human adenomas. Aip-knockdown GH3 cell-conditioned media increases macrophage 40 
migration which is inhibited by the CCL5/CCR5 antagonist maraviroc. Our results suggest that the 41 
tumor microenvironment plays a key role in the invasive nature of AIP mutation positive tumors and 42 
the CCL5/CCR5 pathway is a novel potential therapeutic target.  43 
 44 
 45 
  46 
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Introduction 47 
Heterozygous mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene are present in 48 
about fifth of both familial isolated pituitary adenoma (FIPA) and childhood-onset sporadic 49 
somatotroph adenomas1. Patients with germline AIP mutations (AIPpos) have distinct clinical 50 
features, such as young age at diagnosis, large, invasive, sparsely-granulated adenomas with poor 51 
response to somatostatin analogues1-6. Identification of factors and molecular pathways leading to this 52 
aggressive phenotype are of particular importance to predict tumor behaviour and identify novel 53 
therapeutic targets.  54 
Crosstalk between tumor cells and components of the tumor microenvironment plays a key role in 55 
tumor invasion7-10. The tumor microenvironment includes immune cells, fibroblasts, endothelial cells, 56 
extracellular matrix and numerous secreted soluble factors such as cytokines, altogether representing 57 
a dynamic autocrine-paracrine interaction network that influences tumor behaviour. Relatively sparse 58 
data are available on the tumor microenvironment of pituitary adenomas. Previous studies found low 59 
level of macrophage11 or lymphocyte12 infiltration, while a more recent study showed that the 60 
presence of hematopoietic CD45+ cells was associated with poor clinical outcome13 or invasiveness 61 
in sparsely-granulated somatotroph adenomas14. Understanding interactions between tumor cells and 62 
the tumor microenvironment may therefore provide novel therapeutic targets. 63 
 64 
Our observation of increased macrophage infiltration in AIPpos tumors compared to sporadic 65 
somatotrophinomas, combined with gene expression profiling of freshly-frozen AIPpos samples 66 
indicating altered tumor microenvironment prompted us to study the invasive behaviour of AIPpos 67 
tumors in terms of the microenvironment. We found that tumor-derived cytokine CCL5 is up-regulated 68 
in AIP mutation positive human adenomas. The pituitary-specific Aip-knockout mouse 69 
(AipFlox/Flox;Hesx1Cre/+) revealed that loss of AIP significantly increases macrophage content, similar to 70 
the human AIPpos tumors. In our in vitro experiments, supernatant of a stable Aip-knockdown 71 
somatomammotroph cell line stimulated macrophage migration via CCL5/CCR5 pathway, while 72 
macrophage-derived factors lead to epithelial-to-mesenchymal transition (EMT), increased migration 73 
and invasion in pituitary somatotroph cells.  74 
 75 
 76 
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Results 77 
Analysis of the components of the tumor microenvironment in AIPpos tumors  78 
To understand the tumor microenvironment of AIPpos tumors, we evaluated expression of several 79 
key components of the tumor microenvironment using specific molecular markers for macrophages 80 
(CD68), T-reg cells (FOXP3), cytotoxic T cells (CD8) and memory T cells (CD45RO). Immunostaining 81 
with CD68 showed a remarkable increase in the presence of CD68 positive cells in AIPpos tumors 82 
compared to sporadic adenomas (P=0.01) or normal pituitaries (P=0.001) (Fig. 1A). AIPpos tumors 83 
also expressed a significantly higher number of FOXP3+T-reg cells compared to sporadic adenomas 84 
(P=0.02) or normal tissues (P=0.01) (Fig. 1B). No significant differences were found in cytotoxic (CD8) 85 
or memory T cell (CD45RO) content (Fig. S1A-B).  86 
 87 
EMT signatures in AIPpos tumors 88 
 Microarray gene expression profiling of normal pituitary and familial or sporadic growth hormone 89 
(GH)-secreting tumors (n=15) identified several significantly altered pathways (Table S1). There were 90 
3,025 differentially expressed genes for AIPpos versus normal pituitaries and 1,564 differentially 91 
expressed genes for sporadic tumors versus normal pituitaries. The most significantly altered 92 
canonical pathways are shown in Fig. S2. The ‘Regulation of the Epithelial-Mesenchymal Transition 93 
Pathway’ was one of the most significantly altered pathways (47 genes with 16 up- and 31 94 
downregulated) in AIPpos GH tumors compared to sporadic adenomas (Table 1). Six EMT genes 95 
(CDH1, CTNNB1, ESRP1, EPCAM, PERP and ZEB1) were selected for further validation (Table S2).  96 
 97 
Validation of EMT markers with RT-qPCR and immunohistochemistry 98 
Two step validation using RT-qPCR and immunohistochemistry confirmed our gene expression 99 
profiling data (Table S3 and S4; Fig. 2A and B). E-cadherin (CDH1) mRNA was downregulated in 100 
AIPpos tumors (P=0.004) compared to the normal pituitaries and sporadic GH adenomas (P=0.001) 101 
(Fig. 2A). A significantly lower expression of E-cadherin was seen in AIPpos tumors compared to 102 
normal pituitaries (P=0.0008) and to sporadic somatotrophinomas (P=0.001) (Fig. 2B). No significant 103 
transcript level change was seen for CTNNB1 (cadherin-associated protein, beta-1) coding for β-104 
catenin (Fig. 2A); however, there was a significant difference at the protein level. Normal pituitary 105 
showed strong homogeneous membranous β-catenin staining, whereas absent or weak granular 106 
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membranous beta-catenin expression was observed in 40% of sporadic tumors and 83% of AIPpos 107 
tumors (AIPpos versus normal pituitary P=0.01, AIPpos versus sporadic somatotrophinoma P=0.04) 108 
(Fig. 2B). ESRP1 (epithelial splicing regulatory protein 1), a novel molecular marker of EMT, was 109 
significantly downregulated in AIPpos tumors compared to the normal pituitaries (P=0.005) and 110 
sporadic tumors (P=0.0001) at the mRNA level (Fig. 2A). ESRP1 protein expression was significantly 111 
decreased in AIPpos tumors compared to normal pituitaries (P=0.005) (Fig. 2B). PERP (TP53 112 
apoptosis effector), an EMT-related gene, was significantly downregulated in AIPpos tumors both at 113 
the RNA and protein level compared to normal pituitaries (P=0.01 and 0.03) and to sporadic 114 
somatotrophinomas (P=0.002 and 0.02) (Fig. 2A and B). The significant transcriptional 115 
downregulation of EPCAM, (epithelial cell adhesion molecule; CD326) was confirmed in AIPpos 116 
tumors compared to normal pituitaries (P=0.01) and sporadic adenomas (P=0.004) (Fig. 2A). 117 
Upregulation of ZEB1 (zinc finger E-box binding homeobox 1), one of the master regulators of EMT, 118 
had higher mRNA expression (versus normal pituitary P=0.005) and increased nuclear protein 119 
expression (versus normal pituitary P=0.006; versus sporadic somatotrophinomas P=0.01) (Fig. 2A 120 
and B).  121 
 122 
Macrophage secreted factors induce EMT-like phenotype and enhance migration and invasion 123 
of GH3-Aip-KD cells 124 
AIPpos tumors contain a higher number of macrophages and show an EMT signature corresponding 125 
to recent results linking tumor-associated macrophages with EMT, which might be critical for invasive 126 
behaviour15. Therefore, we investigated the impact of tumor-associated macrophages in the invasive 127 
behaviour of Aip-knockdown GH3 cells using in vitro co-cultures. Freshly isolated rat bone marrow-128 
derived macrophages (confirmed with macrophage markers CD11b and CD68) grown in Roswell Park 129 
Memorial Institute (RPMI) medium were stimulated with 320nM phorbol myristate acetate (PMA) for 130 
24h, then media was replaced with RPMI which was collected at 72h and then used as macrophage-131 
derived conditioned medium (MCM) for the subsequent analysis (Fig. S3A and B). We used lentiviral-132 
transduced shRNA knockdown of Aip in the rat pituitary somatomammotroph cell line GH3 (GH3-Aip-133 
KD) that show 80% reduced AIP protein expression (Fig. S3C). In order to verify the functional effects 134 
of Aip knockdown, we have used two different clones with 50% and 80% level of Aip knockdown. Both 135 
the 50% and 80% knockdowns of Aip show increased proliferation and colony formation compared to 136 
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non-targeting controls (GH3-NT) (Fig. S3D), as previously shown in Aip knockdown4, 16 or knockout 137 
cells17. GH3-Aip-KD (80%) and GH3-NT cells were incubated with MCM. A second set of cells 138 
following 72h MCM treatment were incubated with DMEM for a further 72h, to study if the MCM-139 
induced EMT-like changes could be reversed, representing the mesenchymal-to-epithelial transition 140 
process.  141 
Cell morphology analysis by ImageJ demonstrated that untreated GH3-NT and GH3-Aip-KD cells 142 
show no significant differences in cell size and shape (Fig. 3). MCM-treated GH3-Aip-KD and GH3-NT 143 
cells both underwent EMT-like changes with elongated, spindle-shape mesenchymal morphology 144 
(Fig. 3A). However, these changes were significantly more pronounced in GH3-Aip-KD cells as shown 145 
by cell shape analysis18: they have approximately 62% increased cell surface area, 40% larger 146 
perimeter and become 42% more elongated than the GH3-NT cells (Fig. 3B-D). Roundness and 147 
circularity cell parameters between MCM-treated GH3-Aip-KD and GH3-NT cells were not significantly 148 
different. Cell solidity or stiffness are important features of cellular plasticity19. Solidity index was 149 
decreased for both cell lines following MCM treatment, but GH3-Aip-KD cells had significantly lower 150 
solidity compared to GH3-NT cells, suggesting that these cells are more deformable (Fig. 3G). This 151 
flexibility is required for migration/invasion through the extracellular matrix and we observed this in the 152 
in vitro migration assay where cells need to traverse 8µm pores of transwell inserts (see data below). 153 
After washing off MCM and 72h treatment with DMEM, both cell lines reverted back to a rounded 154 
morphology, with circularity and roundness values returning back to almost one, and showing 155 
increased solidity, representing mesenchymal-to-epithelial transition (Fig. 3E-G).  156 
Analysis of EMT markers by immunofluorescence analysis demonstrated that while untreated cells 157 
show membranous E-cadherin and little cytoplasmic ZEB1 expression, MCM-treated cells show lack 158 
of membranous E-cadherin expression and a significant increase in nuclear and cytoplasmic ZEB1 159 
expression (Fig. 4A). Ingenuity pathway analysis of AIPpos tumors transcriptome identified altered 160 
actin cytoskeleton remodelling pathways. Actin staining of GH3 cells showed that untreated cells have 161 
cortical actin rings. After MCM treatment GH3-NT cells show a granular pattern of actin with less actin 162 
stress fibres and actin spikes whereas GH3-Aip-KD cells showed a mesenchymal phenotype with 163 
elongated morphology with prominent actin stress fibres and numerous actin spikes (Fig. 4A). In the 164 
mesenchymal-to-epithelial transition state, cells re-organise actin cytoskeleton and reverse their 165 
morphology. Western blot analysis showed that expression of E-cadherin was significantly decreased 166 
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(P=0.006) whereas expression of ZEB1 was increased in MCM-treated GH3-Aip-KD cells (P=0.001) 167 
compared to GH3-NT cells (Fig. 4B). These results suggest that macrophage-derived soluble factors 168 
could promote an EMT-like phenotype in rat pituitary GH3 cells.  169 
Next, we assessed the functional consequences of EMT to understand if MCM treatment was altering 170 
migration and invasion capacity of GH3-Aip-KD and GH3-NT cells. There was no difference in 171 
baseline migration between the two cell lines. Incubation with MCM significantly increased cellular 172 
migration of GH3-Aip-KD cells compared to untreated cells (Fig. S4). MCM treatment increased 173 
invasion in both cell types, but more significantly in GH3-Aip-KD (P=0.03) (Fig. 4C). These results 174 
indicate that activated macrophage-derived factors increase migration/invasion of GH3-Aip-KD cells 175 
while GH3-NT shows no or little response.  176 
 177 
The effect of tumor-derived factors on macrophage migration 178 
As we found that macrophage-derived factors significantly altered the phenotypic and functional 179 
characteristics of GH3-Aip-KD cells compared to the GH3-NT cells, we tested effects of tumor-derived 180 
factors on macrophage recruitment: GH3-Aip-KD cell-derived conditioned medium was used as 181 
chemo-attractant for migration of macrophages. Increased macrophage migration was observed 182 
towards the GH3-Aip-KD cell-derived medium compared to GH3-NT cell conditioned medium (Fig. 183 
S5A). These results demonstrate that the GH3-Aip-KD cells release chemotactic factors that might 184 
enable increased migration towards tumor cells. Next, we explored human gene expression data to 185 
search for potential chemotactic factors in AIPpos tumors that could enhance macrophage migration. 186 
Our top candidate was chemokine C-C motif ligand 5 (CCL5). CCL5, also known as RANTES 187 
(regulated upon activation, normal T cell expressed and presumably secreted), a protein known to be 188 
involved in recruitment of macrophages20, was significantly upregulated (~6 fold) in AIPpos tumors 189 
compared to normal pituitary and sporadic tumors. CCL5 is a ligand for the CCR5 receptor expressed 190 
by macrophages. We hypothesised that tumor-derived CCL5 increases macrophage migration via 191 
activating CCR5 on macrophages. To test this hypothesis first we performed macrophage chemotaxis 192 
assays using recombinant CCL5 as chemoattractant and then used the CCR5 inhibitor maraviroc, an 193 
FDA-approved drug, to block their interaction. Recombinant CCL5 increased activated macrophage 194 
migration, and this was inhibited by maraviroc (Fig. S5B). Subsequent experiments using GH3-Aip-195 
KD-conditioned media showed that maraviroc also inhibits macrophage migration towards GH3-Aip-196 
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KD-conditioned media compared to GH3-NT-conditioned media (Fig. 5A) indicating the role of CCL5-197 
CCR5 interaction in this phenomenon. Furthermore, immunohistochemical analysis revealed higher 198 
levels of CCL5 expression in AIPpos tumors than normal pituitary (P=0.001, Fig. 5B) and no 199 
difference between sporadic tumors versus normal pituitaries. CCL5 levels were elevated in GH3-Aip-200 
KD condition media compared to GH3-NT conditioned media (Fig. S5B). To better understand the 201 
mechanism of macrophage recruitment via CCL5 we mined our gene expression profile data to 202 
identify potential regulators of CCL5 in AIPpos tumors. FLI1 (Friend leukaemia virus integration site-203 
1), a transcription factor, was found to be four-fold upregulated in AIPpos tumors compared to the 204 
normal pituitary. There was a significantly increased expression of FLI1 in AIPpos tumors compared 205 
to either sporadic tumors (P=0.003) or normal pituitaries (P=0.02) (Fig. 5C), therefore explaining 206 
upregulated CCL521.  207 
 208 
Loss of AIP increases macrophage infiltrates in Aip-knockout mice 209 
 To determine the relevance of our in vitro findings in vivo, we evaluated the macrophage infiltrate in a 210 
pituitary-specific Aip-knockout mice AipFlox/Flox;Hesx1Cre/+ who develop GH-secreting pituitary tumors 211 
with disruption of the reticulin network (detailed description of this animal model will be reported 212 
separately). Based on our human data, we hypothesised that these animals will develop pituitary 213 
adenomas with significant macrophage infiltration. Immunohistochemical analysis with F4/80 214 
macrophage marker from 15 months old homozygous AipFlox/Flox;Hesx1Cre/+ mice pituitary glands 215 
showed a significant increase in the number of infiltrating macrophages as compared to age-matched 216 
wild-type mice (P<0.05) (Fig. 6), similar to AIP mutation positive human samples. These results 217 
suggest that lack of AIP indeed leads to macrophage infiltration in pituitary tumors.  218 
 219 
Discussion 220 
The tumor microenvironment plays a crucial role in the growth and invasion of tumors7, 8, 10, but this 221 
has not been previously studied in aggressive pituitary tumors associated with AIP mutations. Using 222 
gene expression profiling of AIPpos human pituitary tumor samples, as well as in vitro and in vivo 223 
models, we established that AIPpos tumors have a unique microenvironment strikingly different from 224 
that of sporadic pituitary tumors. We identified increased number of tumor-associated macrophages in 225 
AIPpos tumors compared to sporadic ones. Similar to human AIPpos tumors, pituitary tumors from 226 
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Aip-knockout animals exhibit increased macrophage content suggesting that lack of AIP may be an 227 
important part of the molecular pathway leading to macrophage migration in both mouse and human 228 
pituitary tumors. Tumor-associated macrophages, typically with characteristics of activated 229 
macrophages, are an important component of the tumor microenvironment22, 23 and correlate with 230 
poor prognosis in other tumor types24. Direct interactions between macrophages and tumor cells have 231 
been documented by multiphoton imaging15, 25, and macrophages support tumor cell migration and 232 
invasion by secreting matrix degrading enzymes, such as plasminogen activator, cathepsin B and D 233 
and matrix metalloproteases (MMP) 2 and 926. Indeed, MMP2 and MMP9, known to be associated 234 
with cavernous sinus invasion27, were upregulated in AIPpos samples (Table 1). Tumor-associated 235 
macrophages are linked with EMT28, 29, which is present in AIP deficient samples. Macrophage-236 
derived conditioned medium treated GH3-Aip-KD cells undergo numerous changes associated with 237 
EMT, such as downregulation of E-cadherin and upregulation of ZEB1, remodelling of the 238 
cytoskeleton and increased motility. However, there was no concomitant upregulation of classical 239 
mesenchymal markers, such as N-cadherin and vimentin30-32 in our microarray data suggesting a 240 
partial/incomplete EMT signature in AIPpos tumors. Partial or incomplete EMT has also been 241 
observed in other solid tumours33. Partial EMT was also found in some sporadic GH tumors34, but the 242 
protein expression of AIP was not studied. As pituitary tumors locally invade but only very rarely 243 
metastasise, the partial EMT phenotype would match this clinical observation.  244 
We saw increased expression of FOXP3+T-reg cells in AIPpos tumors compared to sporadic 245 
adenomas and normal pituitary. FOXP3 is a specific T-reg marker that suppresses anti-tumor immune 246 
responses. FOXP3+ T-reg cells are associated with poor prognosis in various cancers35, 36, and 247 
associated with EMT type tumor cells. Interestingly, CCL5, the cytokine we found overexpressed in 248 
AIPpos samples, recruited T-reg cells in a mouse model of pancreatic cancer37. Further studies will be 249 
needed to reveal the functional role of FOXP3 in pituitary tumors and to see whether CCL5 is indeed 250 
involved in recruitment of T-reg cells in AIPpos pituitary tumors.  251 
Ingenuity pathway analysis of the differentially expressed genes of AIPpos, sporadic GH and normal 252 
pituitaries highlighted the EMT pathway as one of the most significantly altered pathways in AIPpos 253 
tumors compared to sporadic adenomas. EMT is a highly conserved cellular process in which cells 254 
lose cell-cell contact and epithelial characteristics, and gain a motile and invasive mesenchymal 255 
phenotype, while mesenchymal-to-epithelial transition participates in the establishment and 256 
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stabilisation of distant metastases. In addition to their key role in development, EMT and 257 
mesenchymal-to-epithelial transition are involved with cancer progression. In AIPpos tumors we 258 
identified a significant number of altered EMT-associated genes, including epithelial markers (CDH1, 259 
CTNNB1, ERSP1 and EPCAM), a transcriptional (ZEB1) and a post-transcriptional regulator 260 
(ESRP1), while there were no statistically significant differences between sporadic adenomas and 261 
normal pituitaries. Therefore, significant disruption of the EMT pathway in AIPpos tumors may cause 262 
their more aggressive phenotype. Gene expression profiling and proteomics studies38-46 led to the 263 
identification of genes associated with invasion and aggressive behaviour42, 47. Changes in EMT 264 
markers have been seen in sporadic somatotroph adenomas with lower E-cadherin and ESRP1 265 
expression34, 48, 49. Loss of ESRP1 in ~90% of AIPpos cases indicates that ESRP1 may be an 266 
important regulator of tumor invasiveness. GH itself has been suggested to stimulate EMT50-52: 267 
autocrine/paracrine GH or treatment with GH induces a complete EMT program and significantly up-268 
regulates the classical mesenchymal markers such as N-cadherin and vimentin in some cancers52-54. 269 
Although high levels of GH raises the possibility that they play a role in the shift towards EMT in 270 
somatotroph tumors, not all somatotroph tumors show EMT and EMT changes were not correlating 271 
with GH levels in sporadic somatotrophinomas34, 48. Comparison of our AIPpos tumor gene expression 272 
profile with that of Aip knockout mouse embryonic fibroblasts55 showed only a modest overlap. This 273 
could be explained by the different cell types as cAMP is stimulating cell proliferation in some cell 274 
types (e.g. adrenal and pituitary) while inhibits in others (e.g. fibroblasts and smooth muscle cells), 275 
and by the fact that AIP tumor suppressor role is specific to the pituitary gland.  276 
While incubation with MCM leads to an EMT-like phenotype in both GH3-NT and GH3-Aip-KD cells, 277 
the degree of change is significantly different. Cell morphology parameters, EMT markers and actin 278 
changes were more pronounced in GH3-Aip-KD cells, supporting the results on increased migration 279 
since in order for cells to invade through the extracellular matrix, filopodia/actin spikes protrude, which 280 
are crucial for successful migration/invasion. Media from macrophages stimulated GH3-Aip-KD cells 281 
to increase migration and invasion, while this cell type typically grown in complete medium do not 282 
show changes in migration/invasion assays56, 57.  283 
Next, we investigated the role of tumor-derived factors on macrophage recruitment. In the tumor 284 
microenvironment tumor cells interact with stromal cells either by cell-cell contacts or via paracrine 285 
signals. We hypothesised that tumor-derived chemokines might direct macrophage homing to the 286 
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tumor microenvironment. We found increased expression of CCL5 in AIPpos tumors compared to the 287 
normal pituitary. Interestingly, our in vitro model confirmed these findings as GH3-Aip-KD cells secrete 288 
more than twice the amount of CCL5 into the media than GH3-NT cells. Elevated levels of CCL5 are 289 
associated with tumor progression in different cancers58. CCL5 is involved in the recruitment of 290 
monocytes, macrophages and other inflammatory cells into inflammatory sites via activation of its 291 
receptors CCR1, CCR3, CCR4, and mainly CCR5. CCL5/CCR5 axis plays an important role in the 292 
progression of a number of solid tumors (breast, ovarian, gastric, cervical, colorectal, and prostate)59. 293 
Maraviroc, a CCR5 antagonist initially approved for treatment of HIV infection, inhibits chemotaxis of 294 
macrophage and monocyte-derived dendritic cells towards CCL560. We demonstrated that CCL5-295 
dependent chemotaxis significantly increased macrophage migration towards the GH3-Aip-KD-296 
conditioned media compared to the GH3-NT-conditioned media and disruption of this signalling by 297 
maraviroc resulted in 50% reduction of macrophage migration. These results suggest that cells 298 
lacking AIP secrete a significant amount CCL5 which can increase macrophage migration toward 299 
these cells and supports macrophage migration into the tumor microenvironment, at least partly, by 300 
CCL5/CCR5 dependent chemotaxis. We also found upregulation of FLI1, the transcriptional regulator 301 
of CCL5, at the gene and protein level in AIPpos tumors21. Aberrant expression of FLI1 is associated 302 
with haematological malignancies and solid tumors61-63. Altered expression of FLI1 is also linked with 303 
tumor aggressiveness63 and poor prognosis64. In our study, we have observed higher levels of FLI1 304 
expression with the concomitant upregulation of CCL5 and the increased number of macrophages in 305 
human AIPpos tumors, supporting a crucial role for FLI1 and CCL5 in macrophage recruitment. 306 
Based on these data, CCL5/CCR5 appears to be a key factor in AIP mutation-related tumorigenesis. 307 
By identifying a novel regulatory pathway, our study raised further interesting questions. Functional 308 
links between AIP, FLI1 and CCL5 or mechanism/s of how AIP silencing stimulates FLI1 and 309 
subsequently CCL5 expression remain to be investigated. The role of AIP in immune-related process 310 
is interesting, since AIP is a co-chaperone of the aryl hydrocarbon receptor (AHR), a known immune 311 
regulator of T helper Th17 cells65, 66. Low level of AHR, which is found in AIPpos tumors67, was found 312 
to be associated with EMT via autophagy, as the autophagy marker BNIP3 is inversely related to AHR 313 
protein levels68. Indeed, we observed a significant upregulation of BNIP3 mRNA in AIPpos tumors.  314 
Limitations of our study include the fact that we used a rat cell line as no human somatotroph pituitary 315 
cell line exists. The tumor microenvironment is complex of several cell types which, in addition to 316 
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macrophages, might affect tumor cell behaviour. Here we focused on macrophages, well known to be 317 
associated with EMT, but other cell types may also influence EMT in AIPpos tumors. We focused on 318 
pro-inflammatory cytokine CCL5 although our microarray data in human samples identified other 319 
significantly differentially expressed cytokines, such as TGFB, CCL4 and osteopontin, which will be 320 
explored in future studies.  321 
In summary, our results using a unique resource of fresh frozen AIPpos tumors show an altered tumor 322 
microenvironment of AIPpos tumors compared to sporadic pituitary adenomas, where tumor-derived 323 
factors, such as CCL5, interact with macrophages resulting in increased infiltration, EMT and more 324 
aggressive phenotype. Furthermore, as somatotroph tumors without AIP mutation can also exhibit low 325 
AIP protein expression, our findings could be relevant for a significant proportion of patients with 326 
somatotrophinomas. Immune infiltrates and EMT signatures might also be useful as biomarkers to 327 
stratify patient groups. Our results establish an important novel crosstalk between tumor cells and the 328 
surrounding tumor microenvironment and suggest potential targets for therapeutic interventions.  329 
330 
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Materials and methods  331 
Pituitary adenoma samples 332 
Fresh frozen AIPpos growth hormone-secreting adenomas (n=6) and sporadic GH-secreting 333 
adenoma (n=4) (Table S5) were obtained at transsphenoidal surgery. A part of each sample was 334 
processed for routine histopathological and immunohistochemical studies, and a part was snap-335 
frozen. Patients with sporadic tumors had no family history of pituitary or other endocrine tumors. 336 
Autopsy pituitary samples (n=5) served as controls. For RT-qPCR validation all the 15 samples used 337 
for microarray analysis were included. For immunohistochemistry studies 8 additional AIPpos 338 
formalin-fixed paraffin-embedded (FFPE) tissue samples as well as pituitary tissue microarray 339 
consisting of 34 sporadic somatotrophinomas and 13 normal pituitaries were used (Table S6). 340 
Gene expression analysis 341 
Gene expression analysis was performed using Affymetrix Human Gene Chip HG-U133 Plus 2.0 342 
array (Affymetrix, Santa Clara, CA, USA) (Supplementary material). Microarray data have been 343 
deposited to the National Centre for Biotechnology Information's Gene Expression Omnibus 344 
(http://www.ncbi.nlm.nih.gov/geo, accession number GSE63357). Ingenuity Pathway Analysis a web-345 
based application (www.ingenuity.com) was used to analyse pathways and biological functions.  346 
Quantitative Reverse Transcriptase PCR (RT-qPCR) 347 
The gene-specific primer/probe sets for CDH1, CTNNB1, ESRP1, PERP, EPCAM and ZEB1 were 348 
purchased from Applied Biosystems (ABI, Foster City, CA, USA; Table S7). For details of RT-qPCR 349 
methods please see Supplementary material.  350 
Protein detection  351 
Immunohistochemical staining and immunoblotting was performed and scored as described in 352 
Supplementary material using primary antibodies listed in Table S8.  353 
Cell line and in vitro functional study 354 
 We used rat pituitary cell line GH3 cells (obtained from European Collection of Authenticated Cell 355 
Cultures at the start of the project) and generated two stable knockdown cell lines, a 50% and an 80% 356 
knockdown, and a non-targeting control (GH3-NT) (Supplementary material). The 80% knockdown 357 
(GH3-Aip-KD) was used for the experiments unless otherwise stated. Cells were cultured in high 358 
glucose Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma, Gillingham, UK) supplemented with 359 
10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin and streptomycin. To collect GH3-360 
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conditioned media for ELISA measurement of CCL5 levels, GH3-Aip-KD and GH3-NT cells were 361 
seeded in six-well plates (2 x106), were grown for 24h in 10% FBS DMEM and, following washing, 362 
incubated for 72h in serum-free DMEM. To collect GH3-conditioned media for macrophage migration 363 
assay, cells (5x106) were grown for 24h in 10% FBS DMEM and, following washing, incubated for 72h 364 
in serum-free DMEM for macrophage migration assays as chemo-attractant. Functional assays were 365 
repeated 3 times and were performed at least in triplicate. 366 
Isolation and characterisation of rat bone-marrow derived macrophages 367 
Macrophages were isolated from rat bone marrow and cultures with granulocyte-macrophage colony-368 
stimulating factor (GM-CSF) in RPMI with 10%, FBS. The expression of macrophage markers CD11b 369 
and CD68 was assessed by immunofluorescence analysis (Supplementary material). At day 7 370 
macrophages were treated with 320nM PMA for 24h and then media was replaced with 10% RPMI. 371 
After 72h this media was collected and used as conditioned medium (MCM) for the subsequent 372 
analysis.  373 
MTS cell proliferation and colony formation assays were performed as described previously4. 374 
 375 
Study approval 376 
The study was approved by the Ethics Committee and patients gave written informed consent. 377 
Cell shape analysis, invasion assay, generation of Aip-knockout mice and statistical analysis are 378 
described in supplementary material. 379 
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Figure legends 655 
Fig. 1 Alterations of the components of the tumor microenvironment in AIPpos tumors. 656 
Immunohistochemical analyses of CD68 and FOXP3 in AIP mutation positive human             657 
somatotroph adenomas (AIPpos), sporadic somatotroph adenomas (Sp GH) and normal pituitaries. 658 
Graphs on the left are showing the percentage of CD68 (A) and FOXP3 (B) positive cells per high 659 
power magnification field, counted on 3-5 random fields at x400. Plotted data were expressed as 660 
mean±SEM. Statistical analysis was performed using Kruskal-Wallis test followed by Conover–Inman 661 
test for individual comparisons, significance between groups are marked as *, <0.05, ***, <0.001. 662 
Representative images (right panels) show more CD68 (macrophages) and FOXP3 positive (T-reg) 663 
cells in AIPpos tumors compared to sporadic somatotroph adenomas. Analyzed number of samples 664 
for normal pituitary, AIPpos tumors and sporadic GH tumors, respectively, are as follows: CD68 (n=9, 665 
9 and 17) and FOXP3 (n=11, 9 and 17). All images are x200 magnification and scale bar=100µm. 666 
 667 
Fig. 2 Validation of the selected EMT markers at the mRNA and protein levels. (A) RT-qPCR 668 
validation of downregulated (CDH1, CTNNB, ESRP1, PERP and EPCAM) and upregulated (ZEB1) 669 
EMT genes. RNA expression of the down- and upregulated genes in AIPpos tumors (n=6) compared 670 
to normal pituitaries (n=5) and sporadic GH tumors (n=3) show confirmation of the gene expression 671 
profile data. (B)  Immunohistochemical analysis of downregulated (CDH1, CTNNB, ESRP1 and 672 
PERP) and upregulated (ZEB1) EMT genes. Protein expression in graphical form and with 673 
representative images in AIPpos tumors compared to normal pituitaries and sporadic GH tumors. E-674 
cadherin: Normal pituitary cells are showing uniform strong to moderate membranous staining. 675 
AIPpos GH tumor displays weak diffuse cytoplasmic positivity without any membranous staining. 676 
Sporadic GH adenoma shows membranous and granular cytoplasmic positivity. Beta-catenin: Normal 677 
pituitary cells are showing strong to moderate membranous immunoreactivity. AIPpos GH tumor 678 
displays discontinuous cytoplasmic expression. Sporadic GH shows membranous and granular 679 
cytoplasmic positivity. ESRP1: Normal pituitary cells are showing strong cytoplasmic 680 
immunoreactivity. AIPpos GH tumor shows weak cytoplasmic expression. Sporadic GH tumor shows 681 
universal cytoplasmic and moderate to strong nuclear positivity. PERP: Normal pituitary cells are 682 
showing strong granular cytoplasmic positivity. AIPpos GH tumor shows cytoplasmic expression with 683 
the nuclear atypia. Sporadic GH tumor shows granular cytoplasmic and nuclear positivity of variable 684 
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strength. ZEB1: Normal pituitary cells are completely negative. AIPpos GH tumor exhibits uniform 685 
moderate to strong positive nuclear staining. Sporadic GH tumor shows weak to moderate nuclear 686 
staining in the majority of the tumor cells. Overall P value for multiple comparison is shown in the left 687 
upper corner of each graph, while significance between groups are marked with *, <0.05, **, <0.01, 688 
***, <0.001 (Kruskal-Wallis test followed by Conover–Inman test). All images are x400 magnification 689 
and scale bar=50µm. 690 
 691 
Fig. 3 Macrophage-conditioned media induce EMT-like phenotype in GH3-Aip-KD cells. (A) 692 
Macrophage-conditioned media (MCM) induces an EMT-like phenotype. Morphological changes in 693 
GH3-Aip-KD and control GH3-NT (representative phase contrast images, top panels) and 694 
quantification of cell morphology (bottom panels). Untreated and mesenchymal-to-epithelial transition 695 
state (replaced with DMEM) GH3-Aip-KD and GH3-NT cells showed an epithelial cobblestone-like 696 
morphology (phase contrast images: 1st, 3rd, 4th and 6th panels) whereas MCM-treated cells both GH3-697 
NT and GH3-Aip-KD become spindle shaped and show mesenchymal like morphology (phase 698 
contrast images: 2nd and 5th panels). Untreated GH3-NT and GH3-Aip-KD cells show no significant 699 
differences in cell size and shape.  700 
Morphology of the cells was quantified using six different parameters (ImageJ). Around one hundred 701 
cells from each condition were evaluated. There was an increase in cell area (B) and perimeter (C) in 702 
MCM-treated GH3-NT and GH3-Aip-KD cells, while, cells without MCM treatment showed no 703 
difference. (D) Feret’s diameter (measure of cell elongation) was significantly higher in MCM-treated 704 
cells, indicating more elongated cell shape. (E and F) Circularity and roundness (a value closer to one 705 
is indicate more circular/rounded cells and close to zero indicated an elongated shape): untreated and 706 
mesenchymal-to-epithelial transition state cells of GH3-NT and GH3-Aip-KD showed more circular 707 
and rounded shape than MCM-treated cells. (G) Solidity, defined as the ratio of cell area to the 708 
enclosing convex polygon area, indicates the stiffness and deformability of cells, was decreased in 709 
both GH3-NT and GH3-Aip-KD cells undergoing EMT. Overall P value for multiple comparison is 710 
shown in the left upper corner of the graphs, while significance between groups are marked with *, 711 
<0.05, ***, <0.001 (two-way ANOVA with Bonferroni multiple comparison test). n=3, performed in 712 
triplicates on three independent days. Scale bar=25µm. 713 
 714 
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Fig. 4 Alterations of the EMT markers in GH3-NT and GH3-Aip-KD cells. (A) Immunofluorescence 715 
analysis of E-cadherin, ZEB1 and actin in GH3-NT and GH3-Aip-KD cells with or without MCM at 72h. 716 
Untreated cells of GH3-NT and GH3-Aip-KD cells show membranous localization of E-cadherin and 717 
low level of cytoplasmic ZEB1 expression, while MCM-treated cells show lack of membranous but 718 
increased cytoplasmic E-cadherin expression and a significant increase in nuclear and cytoplasmic 719 
ZEB1 expression. After removal of MCM and culturing cells in 10% DMEM for 72h, the cells revert 720 
back to their cobblestone-like morphology (mesenchymal-to-epithelial transition state), increased E-721 
cadherin expression and localization as well as reduced ZEB1 expression. Actin staining revealed 722 
that untreated cells show cortical rings of actin. MCM-treated GH3-NT cells show granular pattern of 723 
actin with less actin stress fibers while GH3-Aip-KD cells showed prominent actin stress fibers and 724 
numerous actin spikes (inset). In contrast, in mesenchymal-to-epithelial transition state cells are 725 
gradually return to the original state of their actin cytoskeleton (63x magnifications). DAPI was used to 726 
stain the nuclei; the pictures are representative of at least three experiments. (B) Immunoblotting 727 
(densitometric analysis and representative images) suggested that E-cadherin levels were 728 
significantly decreased and ZEB1 significantly increased in MCM-treated GH3-Aip-KD cells compared 729 
to GH3-NT cells. Overall P value for multiple comparison is shown, while significance between groups 730 
are marked with **, <0.01, ***, <0.001; two-way ANOVA followed by Newman-Keuls multiple 731 
comparison test. (C) Invasion assays showing that MCM treatment increases the invasion of GH3-NT 732 
and GH3-Aip-KD cells. Bar charts show the mean number of invading cells through the Matrigel-733 
coated transwell chambers measured after 72h. Both GH3-NT and GH3-Aip-KD cells show significant 734 
increase in invasion compared to the untreated cells, but was more significant in GH3-Aip-KD cells. 735 
Representative photographs of invading cells are shown (x10), right panels. P values indicated *, 736 
<0.05, **, <0.01; two-way ANOVA, Newman-Keuls multiple comparison test. Data represent mean 737 
values of three independent experiments. 738 
 739 
Fig. 5 The role of the CCL5 pathway in macrophage migration. (A) Migration assays showing that 740 
macrophage migration was significantly reduced towards GH3-Aip-KD cells derived conditioned 741 
media compared to GH3-NT control cells derived conditioned media. Macrophages were in vitro 742 
treated with maraviroc (200nM) for 24h and the migration in response to GH3-Aip-KD conditioned 743 
media and GH3-NT conditioned media was evaluated. Cells were counted in nine random fields and 744 
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data is presented as mean±SEM, n=3. Graph showing the percentage of the MVC treated migrated 745 
macrophages towards the GH3-NT and GH3-Aip-KD conditioned medium relative to the vehicle. V, 746 
vehicle, MVC, maraviroc. P values indicated  ***, <0.001; t-test. (B) Immunohistochemical analysis of 747 
CCL5 in normal pituitary (NP, n=11), AIP mutation positive somatotroph adenomas (AIPpos GH, 748 
n=12) and sporadic somatotroph adenomas (Sp GH, n=17). Graph showing that CCL5 is highly 749 
upregulated in AIPpos tumors compared to the normal pituitary (left panel). Right panels show the 750 
representative images of CCL5 staining. P values indicated **, <0.01; one-way ANOVA with 751 
Bonferroni multiple comparison test. All images are x200 magnification and scale bar=100µm. (C) 752 
Immunohistochemical analysis of FLI1 in normal pituitary (NP, n=11), AIP mutation positive 753 
somatotroph adenomas (AIPpos GH, n=12) and sporadic somatotroph adenomas (Sp GH, n=17). 754 
Graph showing that FLI1 is highly upregulated in AIPpos tumors compared to the normal pituitary (left 755 
panel) and Sp GH tumors (left panel). Right panels show the representative images of FLI1 staining. 756 
P values indicated ***, <0.001; one-way ANOVA with Bonferroni multiple comparison test. All images 757 
are x200 magnification and scale bar=100µm. 758 
 759 
Fig. 6 Loss of AIP increases macrophage infiltrates in the Aip-knockout mice. Reticulin staining of 760 
wild-type (WT) and homozygote knockout (AipFlox/Flox;Hesx1Cre/+) pituitary tissue showing disrupted 761 
reticulin network in the knockout animal. The bar graphs show the increased number of macrophages 762 
in Aip-knockout mice compared to the wild-type. Representative images of macrophage infiltration in 763 
wild-type and homozygote Aip-knockout mice as determined by F4/80 staining and quantified as the 764 
percentage of F4/80+ cells. Representative immunostaining with F4/80 mouse macrophage marker 765 
(data from n=4 mice/genotype). Student’s t-test, *, P<0.05. Scale bar=50µm. 766 
 767 
  768 
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Table 1 47 known EMT-related genes in AIPpos somatotroph adenomas 769 
Symbol Entrez Gene Name Affymetrix Fold 
change 
ADAM17 ADAM metallopeptidase domain 17 205746_s_at 2.32 
AKT3 v-akt murine thymoma viral oncogene homolog 3 242876_at -2.92 
APC adenomatous polyposis coli 203527_s_at 2.80 
BRAF B-Raf proto-oncogene, serine/threonine kinase 206044_s_at -3.90 
CDH1 cadherin 1, type 1, E-cadherin (epithelial) 201131_s_at -27.00 
CDH2 cadherin 2, type 1, N-cadherin (neuronal) 203440_at -17.74 
CLDN3 claudin 3 203954_x_at -3.14 
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 223679_at -4.07 
EGFR epidermal growth factor receptor 224999_at -5.65 
EPCAM epithelial cell adhesion molecule 201839_s_at -2.42 
ESRP1 epithelial splicing regulatory protein 1 225846_at -32.31 
ESRP2 epithelial splicing regulatory protein 2 219395_at -5.92 
FGF13 fibroblast growth factor 13 205110_s_at -7.93 
FGFR1 fibroblast growth factor receptor 1 222164_at -4.63 
FGFR2 fibroblast growth factor receptor 2 203638_s_at -4.64 
FGFR3 fibroblast growth factor receptor 3 204379_s_at -9.55 
FZD3 frizzled class receptor 3 239082_at -7.35 
FZD5 frizzled class receptor 5 221245_s_at -3.71 
FZD7 frizzled class receptor 7 203706_s_at -15.41 
GSK3B glycogen synthase kinase 3 beta 226183_at 2.89 
HGF hepatocyte growth factor (hepapoietin A; scatter factor) 209960_at -4.20 
HRAS Harvey rat sarcoma viral oncogene homolog 212983_at -2.11 
JAG2 jagged 2 32137_at -2.97 
JAK1 Janus kinase 1 239695_at -4.41 
LEF1 lymphoid enhancer-binding factor 1 221558_s_at 3.57 
LOX lysyl oxidase 215446_s_at 2.76 
MAP2K5 mitogen-activated protein kinase kinase 5 204756_at 2.01 
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MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 
72kDa type IV collagenase) 
201069_at 4.95 
MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase) 
203936_s_at 2.82 
NOTCH2 notch 2 202443_x_at -4.95 
PERP PERP, TP53 apoptosis effector 222392_x_at -3.73 
PIK3C2A phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit 
type 2 alpha 
241905_at -7.36 
PIK3C3 phosphatidylinositol 3-kinase, catalytic subunit type 3 232086_at 3.85 
PIK3CB phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic 
subunit beta 
217620_s_at -2.41 
PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic 
subunit gamma 
239294_at 4.24 
PSENEN presenilin enhancer gamma secretase subunit 218302_at 2.92 
RELA v-rel avian reticuloendotheliosis viral oncogene homolog A 201783_s_at -2.10 
RRAS2 related RAS viral (r-ras) oncogene homolog 2 212589_at -4.12 
SMAD2 SMAD family member 2 203076_s_at 2.50 
SMAD3 SMAD family member 3 218284_at -4.13 
TCF4 transcription factor 4 212385_at 2.92 
TCF7L1 transcription factor 7-like 1 (T-cell specific, HMG-box) 221016_s_at -2.41 
TGFB2 transforming growth factor, beta 2 209909_s_at 8.74 
TWIST1 twist family bHLH transcription factor 1 213943_at -4.84 
WNT4 wingless-type MMTV integration site family, member 4 208606_s_at 7.04 
WNT5A wingless-type MMTV integration site family, member 5A 213425_at -4.70 
ZEB1 zinc finger E-box binding homeobox 1 210875_s_at 3.64 
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